France to tighten up drug trial rules after fatal incident

France to tighten up drug trial rules after fatal incident
This Friday, Jan. 15, 2016 file photo shows a logo of the Biotrial laboratory displayed on its building in Rennes, western France. France's health minister has presented a plan to tighten up the rules regarding human drug trials following an experimental test that killed a volunteer in January. (AP Photo/David Vincent, File)

France's health minister presented a plan on Monday to tighten the rules regarding human drug trials following an experimental test that killed a volunteer in January.

The minister, Marisol Touraine, also demanded that the Biotrial company which carried out the fatal trial provide an action plan within a month to guarantee that "major breaches" cannot happen again.

"If they don't, we will suspend their activities. If this report is handed in, we will carry out verifications by the end of the year", Touraine said in a news conference.

"This accident should have been reported without delay to the National Agency for Drug safety," she said. "But the laboratory only reported it formally on Thursday, Jan. 14, four days after the first volunteer was taken to a hospital and three days after the decision was made to suspend the test."

Touraine stressed that the investigation by the health administration showed that the conditions under which the trial by the Rennes-based firm were authorized were "compliant with the current legislation," but there were breaches in the way Biotral handled the problem.

The trial for the Portuguese pharmaceutical company Bial involved 90 . It was stopped after six people became seriously ill, and one died.


Explore further

'Major shortcomings' in French drug trial death lab: inquiry

© 2016 The Associated Press. All rights reserved.

Citation: France to tighten up drug trial rules after fatal incident (2016, May 23) retrieved 15 August 2020 from https://medicalxpress.com/news/2016-05-france-tighten-drug-trial-fatal.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
0 shares

Feedback to editors

User comments